Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

Company profile
Ticker
NYMX
Exchange
Website
CEO
Paul Averback
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
NYMX stock data
News

Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
12 Aug 22
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Aug 22
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
11 Aug 22
11 Health Care Stocks Moving In Monday's Pre-Market Session
25 Jul 22
12 Health Care Stocks Moving In Friday's After-Market Session
22 Jul 22
Calendar
30 Mar 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 May 22 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 1.65 | 1,151,515 | 1.9M | 4,702,065 |
2 May 22 | Robinson James George | Warrant Common stock | Buy | Acquire P | No | No | 2 | 1,151,515 | 2.3M | 1,151,515 |
22 Apr 21 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 2.085 | 200 | 417 | 3,550,550 |
22 Apr 21 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 2.0882 | 1,100 | 2.3K | 3,550,350 |
22 Apr 21 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 2.0899 | 2,900 | 6.06K | 3,549,250 |
22 Apr 21 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 2.1 | 800 | 1.68K | 3,546,350 |
22 Apr 21 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 2.08 | 51 | 106.08 | 3,545,550 |
22 Apr 21 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 2.0899 | 4,949 | 10.34K | 3,545,499 |
22 Apr 21 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 2.05 | 5,000 | 10.25K | 3,540,550 |
22 Apr 21 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 2.105 | 3,100 | 6.53K | 3,535,550 |
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
alter, anniversary, Aveback, communicated, communicating, communication, concurrent, Culter, customary, exemplary, ID, issuable, reclassified, reward, thousand
Removed:
waived
Current reports
6-K
Current report (foreign)
7 Jul 22
6-K
2022 Q1
Current report (foreign)
13 May 22
6-K
Nymox Announces Closing of $6.4 Million Registered Direct Offering
22 Mar 22
6-K/A
Notice of the Annual General Meeting of the Shareholders
22 Nov 21
6-K
Notice of the Annual General Meeting of the Shareholders
19 Nov 21
6-K
2021 Q3
Current report (foreign)
12 Nov 21
6-K
2021 Q2
Current report (foreign)
13 Aug 21
6-K
2021 Q1
Current report (foreign)
14 May 21
6-K
Nymox Announces $8,000,000 Private Placement
6 May 21
6-K
Notice of the Annual General Meeting of the Shareholders
20 Nov 20
Registration and prospectus
F-3
Shelf registration (foreign)
29 Mar 22
424B5
Prospectus supplement for primary offering
22 Mar 22
F-3
Shelf registration (foreign)
9 Dec 21
F-3
Shelf registration (foreign)
11 May 21
424B5
Prospectus supplement for primary offering
14 Aug 20
424B5
Prospectus supplement for primary offering
13 Aug 20
424B5
Prospectus supplement for primary offering
17 Jul 20
F-3
Shelf registration (foreign)
3 Apr 20
424B5
Prospectus supplement for primary offering
8 Feb 16
F-3
Shelf registration (foreign)
13 Jul 15
Proxies
No filings
Other
EFFECT
Notice of effectiveness
13 Apr 22
CORRESP
Correspondence with SEC
5 Apr 22
UPLOAD
Letter from SEC
3 Apr 22
EFFECT
Notice of effectiveness
31 Jan 22
CORRESP
Correspondence with SEC
24 Jan 22
UPLOAD
Letter from SEC
21 Dec 21
EFFECT
Notice of effectiveness
21 May 21
CORRESP
Correspondence with SEC
16 May 21
UPLOAD
Letter from SEC
13 May 21
EFFECT
Notice of effectiveness
13 May 20
Ownership
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
6 May 22
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
27 Apr 21
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
12 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
10 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
9 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
3 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
2 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
1 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
28 Jun 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
27 Jun 19
Patents
Utility
Method of Enhancing the Therapeutic Efficacy of Fexapotide Triflutate In Treating Luts
21 Jul 22
Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year.
Utility
Focal treatment of prostate cancer
17 May 22
The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.
Utility
Method of treating lower urinary tract symptoms with fexapotide triflutate
22 Mar 22
Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient.
Utility
Methods of treating multifocal cancer
25 Jan 22
The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.
Utility
Focal Treatment of Prostate Cancer
4 Feb 21
The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.
Reddit threads
Daily Discussion Thread - August 12th, 2022
12 Aug 22
Daily Discussion Thread - August 11th, 2022
11 Aug 22
Daily Discussion Thread - May 13th, 2022
13 May 22
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - April 1st, 2022
1 Apr 22
Daily Discussion Thread - November 12th, 2021
12 Nov 21
Daily Discussion Thread - November 11th, 2021
11 Nov 21
Daily Discussion Thread - November 10th, 2021
10 Nov 21
Daily Plays October 03, 2021
2 Oct 21
Daily Discussion Thread - August 16th, 2021
16 Aug 21